Association of IL-1A and IL-1B polymorphisms with ankylosing spondylitis among the Chinese Han population: a case–control study

Lei Li1,2,*, Baolan Shi1,4,*, Wenkai Zheng1,2, Wenhua Xing2, Yan Zhao2, Feng Li2, Daqi Xin2, Tianbo Jin3, Yong Zhu2, Xuejun Yang2

1Inner Mongolia Medical University, Hohhot 010020, China
2The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010030, China
3Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, Xi’an, Shaanxi 710069, China
4Inner Mongolia Medical University, Chifeng Clinical Medical College, Chifeng, 024000, China

*Joint first authors

Correspondence to: Yong Zhu, email: 1036227632@qq.com
Xuejun Yang, email: yangxuejun2004@126.com

Keywords: ankylosing spondylitis (AS), single nucleotide polymorphism (SNP), IL-1A, IL-1B, case-control study

Received: September 24, 2016 Accepted: February 21, 2017 Published: March 08, 2017

ABSTRACT

Ankylosing spondylitis (AS) is a complex and chronic inflammatory disease with a high heritage. Previous study has shown that IL-1A and IL-1B involved in inflammatory reaction. But little is known about single nucleotide polymorphisms (SNPs) of IL-1A and IL-1B associated with AS. We conducted a case-control study among 267 AS cases and 297 healthy controls from China. In the genetic model analysis, we found the “T” genotype of rs3783550 was associated with decreased AS risk in the dominant model ($p = 0.044$) and log-additive model ($p = 0.023$); the “C” genotype of rs3783546 was significantly associated with decreased AS risk based in the dominant model ($p = 0.044$) and log-additive model ($p = 0.023$). Additionally, the minor allele “A” of rs2853550 may also reduce the risk of AS in dominant ($p = 0.025$) and log-additive model ($p = 0.024$). Our results suggested that the polymorphisms of IL-1A and IL-1B are associated with the AS susceptibility in the Chinese Han population. Further studies are needed to characterize the functional sequences that cause AS.

INTRODUCTION

Ankylosing spondylitis (AS) is a complex and chronic inflammatory disease with a high heritage. The overall prevalence of AS in Chinese is 0.2–0.54% [1]. The condition affects predominantly the axial skeleton, including the spine and sacroiliac joints, and causes pain, stiffness, and, eventually, bony ankylosis. Joints and tendon insertions (entheses) else where are also commonly involved, and approximately one-third of patients develop acute anterior uveitis.

Although AS is also a complex multifactorial disease resulting from gene and environment interaction, the exact mechanism of AS is still unclear. As we all know, Genetic factors have an importance role in AS susceptibility and expression [2]. HLA–B27 is the major gene associated with the susceptibility of AS, which is present in > 95% of Caucasians of northern European ancestry, yet only 1%–5% of HLA-B27 carriers develop AS, so that HLA-B27 carriage alone does not explain the pattern of disease recurrence in families [3]. Therefore, we provide a hypothesis that HLA-B27 is almost essential but not adequate to cause AS and that other genes interact with HLA-B27 to cause the condition. Recent genome-wide screening identified non-MHC regions with linkage with AS [4, 5]. The interleukin-1 (IL-1) cluster on chromosome 2q has emerged as a robust non-MHC susceptibility locus for AS in several groups study [5–7]. Those studies, however, always have conflicting results in different populations, making it difficult to put forward a conclusion about the relationship between IL-1 gene cluster and AS. Due to the IL-1 gene cluster also play a prominent role in inflammation and host defense against infection. The prototypic members of the IL-1 family gene cluster are the
genes *IL-1A*, *IL-1B*, and *IL-1RN* [5], which were related to AS, but *IL-1A* and *IL-1B* were less reported [4, 5, 8, 9]. *IL-1A* and *IL-1B* encode proinflammatory cytokines involved in host defense against infection [5]. The genes polymorphisms have been related to a number of chronic inflammatory diseases such as Crohn’s disease and inflammatory bowel disease (IBD) [10, 11]. Rs16944 in *IL-1B* was identified associated with AS in European ancestry [5], but was not replicated in another study in a Han Chinese population, and few information is found about other SNPs on *IL-1A* and *L-1B* associated with AS risk. Besides, recent report has showed that association particularly with haplotypes of single nucleotide polymorphisms (SNPs) in the IL1RN gene [4], suggesting that the true associated polymorphism lay on the associated haplotype but was not one of the individual markers genotype.

Thus, in consideration of these circumstances, we sought to test whether *IL-1* genes were associated with AS in Chinese Han population, which is previously associated with AS in Europe population.

**RESULTS**

A total of 276 cases and 296 controls were enrolled in our study. The demographic characteristics of the study population are showed in Table 1, which showed the significant difference in age and gender distribution between the case and control groups (*p* < 0.001).

Table 2 summarized the minor allelic frequency (MAF) of tested SNPs among the individuals in the case and control groups. After Hardy–Weinberg equilibrium (HWE) *p* value screening, we excluded one SNP (rs2853550). The allelic frequency of SNPs in the controls group was similar to those of the HapMap Asian population. Through the χ² test, we found that no SNP was significantly associated with AS risk.

The minor allele of each SNP was assumed a risk allele compared to the wild-type allele. MAF in cases and controls are listed in Table 3. Five models (co-dominant model, over-dominant model, log-additive model additive model, dominant model and recessive model) were applied for analyzing the association between polymorphisms and AS, which was modified by the age of the subjects. We found that the risk allele “T” of rs3783550 was associated with a decreased risk of AS based on dominant model (OR = 0.56, 95% CI = 0.32–0.99, *p* = 0.044), and log-additive model (OR = 0.61, 95% CI = 0.39–0.94, *p* = 0.023). The minor allele “C” of rs3783546 was associated with a decreased AS risk under dominant model (OR = 0.56, 95% CI = 0.32–0.99, *p* = 0.044), and log-additive model (OR = 0.61, 95% CI = 0.39–0.94, *p* = 0.023). Additionally, the minor allele “A” of rs2853550 may also reduce the risk of AS based on the dominant (OR = 0.36, 95% CI = 0.15–0.81, *p* = 0.014) and log-additive model (OR = 0.41, 95% CI = 0.18–0.91, *p* = 0.024). However, no statistically significant evidence suggested that the other polymorphisms tested were associated with AS risk.

Two blocks were detected in studied *IL-1A* and *IL-1B* SNPs by haplotype analyses (Figure 1). The results of the association between the *IL-1A* and *IL-1B* haplotype and the risk of AS were listed in Table 4. Haplotype “TCG” of *IL-1A* in Block were found to be associated with decrease risk of AS (OR = 0.36, 95% CI = 0.16–0.81 *p* = 0.014).

![Figure 1: LD analysis of the association between all the SNPs of the IL-1A and IL-1B gene and ankylosing spondylitis.](image-url)
DISCUSSION

In this Chinese Han population-based case–control study, we investigated the associations between the 12 SNPs and risk of AS. We found the associations between \textit{IL-1A} and \textit{IL-1B} SNPs and the risk of AS, rs3783550, rs3783546 and rs2853550 showed a protective effect on AS risk. The haplotype “TCG” of \textit{IL-1A} were significant associated with a decreased risk of AS, which can act as a protect factor for AS. Although the individual polymorphism investigated showed no association with AS adjusted by age and sex, it is contribute to our hypothesis that substantially stronger haplotype associations with SNPs of \textit{IL-1A} than with individual SNPs.

\textit{IL-1A} and \textit{IL-1B} are one of the family of IL-1 and are proinflammatory cytokine that are mainly produced by activated macrophages, whose actions include augmentation of activation of T and B lymphocytes and monocyte/macrophages, and induce fibroblast proliferation leading to synovial pannus formation [12], which also produce IL-1\alpha and IL-1\beta, respectively [13, 14]. The genes for the proinflammatory cytokines IL-1\alpha and IL-1\beta are located on the long arm of human chromosome 2, in close linkage with another gene of the \textit{IL-1} gene family, the gene encoding their endogenous antagonist IL-1Ra [15]. Randomized clinical trials in rheumatoid arthritis with recombinant human IL-1ra demonstrated modest anti-inflammatory effects and significant slowing in the rate of joint damage [16]. This may suggest that in certain patients the lack of production of IL-1ra, the natural antagonist of IL-1\beta, contributes to the chronicity of the inflammation. Furthermore, \textit{IL1A} and \textit{IL1B} may induce inflammation in AS through intracellular effects [17], it is also possible that \textit{IL1A} and \textit{IL1B} are involved in the initiation of disease, but has a less significant role in established disease.

A previous study found that rs3783550 was significantly associated with reduced AS risk in Canadian

| Variables Case (n = 267) | Control (n = 297) | Total | P*a |
|--------------------------|-------------------|-------|-----|
| Sex < 0.001a             |                   |       |     |
| Female                   | 67 (25.1%)        | 198 (66.7%) | 265 |
| Male                     | 200 (74.9%)       | 99 (33.3%)  | 299 |
| Age, yr (mean ± SD)      | 31.58 ± 12.28     | 56.35 ± 9.72 | < 0.001b |

*aPearson’s test; 
bWelch’s test.

| SNP ID      | Genes | Role     | Allels | HWE P-value | MAF Case | Control | ORs  | 95 % CI     | P*  |
|-------------|-------|----------|--------|-------------|----------|---------|------|-------------|-----|
| rs3783550   | IL1A  | Intron   | T/G    | 0.790       | 0.337    | 0.320   | 1.08 | 0.84–1.39   | 0.539|
| rs3783546   | IL1A  | Intron   | C/G    | 0.894       | 0.337    | 0.319   | 1.08 | 0.85–1.39   | 0.523|
| rs2856838   | IL1A  | Intron   | A/G    | 0.748       | 0.253    | 0.235   | 1.10 | 0.84–1.45   | 0.482|
| rs1609682   | IL1A  | Intron   | T/G    | 0.789       | 0.327    | 0.321   | 1.08 | 0.84–1.38   | 0.564|
| rs3783521   | IL1A  | Promoter | G/A    | 0.790       | 0.306    | 0.320   | 1.08 | 0.84–1.39   | 0.539|
| rs2853550   | IL1B  | Downstream | A/G  | 0.032a      | 0.082    | 0.082   | 1.01 | 0.66–1.55   | 0.963|
| rs1143643   | IL1B  | Intron   | C/T    | 0.350       | 0.444    | 0.475   | 0.88 | 0.70–1.12   | 0.302|
| rs3136558   | IL1B  | Intron   | G/A    | 1.000       | 0.380    | 0.380   | 1.00 | 0.79–1.27   | 0.998|
| rs1143630   | IL1B  | Intron   | T/G    | 0.656       | 0.180    | 0.153   | 1.21 | 0.88–1.66   | 0.231|
| rs1143627   | IL1B  | Promoter | G/A    | 0.412       | 0.466    | 0.486   | 0.92 | 0.73–1.17   | 0.500|
| rs16944     | IL1B  | Promoter | A/G    | 0.416       | 0.470    | 0.478   | 0.97 | 0.77–1.22   | 0.787|
| rs1143623   | IL1B  | Promoter | G/C    | 0.398       | 0.399    | 0.408   | 0.96 | 0.76–1.22   | 0.762|

HWE: Hardy-Weinberg equilibrium; MAF: Minor allelic frequency
OR: odds ratio; 95%CI: 95%confidence interval;
SNP: Single-nucleotide polymorphism;
 Minor allele;
p ≤ 0.05 indicates statistical significance;
HWE p ≤ 0.05 was excluded.
Table 3: Logistic regression analysis of the association between the SNPs and ankylosing spondylitis disease (adjusted sex and age)

| SNP   | Model     | Genotype | Case           | Control        | OR (95% CI)     | p*    | AIC  | BIC  |
|-------|-----------|----------|----------------|----------------|----------------|-------|------|------|
|       |           | G/G      | 136 (45.8%)    | 117 (43.8%)    | 1.00           | 0.073 | 323.2| 344.8|
| rs3783550 | Codominant | G/T      | 132 (44.4%)    | 120 (44.9%)    | 0.63 (0.34–1.14) | 0.044* | 323.2 | 339.7 |
|        |           | T/T      | 29 (9.8%)      | 30 (11.2%)     | 0.35 (0.13–0.99) |       |      |      |
|        |           | G/G      | 136 (45.8%)    | 117 (43.8%)    | 1.00           | 0.009 | 323.5 | 340.8 |
|        | Dominant  | G/T-T/T  | 161 (54.2%)    | 150 (56.2%)    | 0.56 (0.32–0.99) |       |      |      |
|        | Recessive | G/G-G/T  | 268 (90.2%)    | 237 (88.8%)    | 1.00           | 0.090 | 323.5 | 340.8 |
|        |           | T/T      | 29 (9.8%)      | 30 (11.2%)     | 0.43 (0.16–1.17) |       |      |      |
|        | Overdominant | G/G-T/T  | 165 (55.6%)    | 147 (55.1%)    | 1.00           | 0.300 | 325.3 | 342.7 |
|        |           | G/T      | 132 (44.4%)    | 120 (44.9%)    | 0.74 (0.41–1.32) | 0.023* | 321.2 | 338.5 |
|        | Log-additive | —        | —              | —              | 0.61 (0.39–0.94) |       |      |      |
|        |           | G/G      | 136 (46%)      | 117 (43.8%)    | 1.00           | 0.074 | 323.1 | 344.8 |
|        |           | G/C      | 131 (44.3%)    | 120 (44.9%)    | 0.63 (0.34–1.14) | 0.074 | 323.1 | 344.8 |
|        | Dominant  | C/C      | 29 (9.8%)      | 30 (11.2%)     | 0.35 (0.13–0.99) |       |      |      |
|        |           | G/G      | 136 (46%)      | 117 (43.8%)    | 1.00           | 0.044* | 322.3 | 339.6 |
|        | Recessive | G/G-C/C  | 160 (54%)      | 150 (56.2%)    | 0.56 (0.32–0.99) |       |      |      |
|        |           | G/C      | 131 (44.3%)    | 120 (44.9%)    | 0.63 (0.34–1.14) | 0.090 | 325.3 | 340.8 |
|        | Overdominant | G/G-C/C  | 165 (55.7%)    | 147 (55.1%)    | 1.00           | 0.310 | 325.3 | 342.6 |
|        |           | G/C      | 131 (44.3%)    | 120 (44.9%)    | 0.74 (0.41–1.32) | 0.023* | 321.2 | 338.5 |
|        | Log-additive | —        | —              | —              | 0.61 (0.39–0.94) |       |      |      |
|        |           | G/G      | 251 (85.4%)    | 227 (85%)      | 1.00           | 0.076 | 322   | 343.6 |
|        |           | A/G      | 38 (12.9%)     | 36 (13.5%)     | 0.38 (0.15–1.00) | 0.026 | 322   | 343.6 |
|        | Codominant | A/A      | 5 (1.7%)       | 4 (1.5%)       | 0.22 (0.02–3.31) |       |      |      |
|        |           | G/G      | 251 (85.4%)    | 227 (85%)      | 1.00           | 0.025* | 320.1 | 337.4 |
|        | Dominant  | A/G-G/G  | 43 (14.6%)     | 40 (15%)       | 0.36 (0.15–0.91) |       |      |      |
|        | Recessive | G/G-A/G  | 289 (98.3%)    | 263 (98.5%)    | 1.00           | 0.290 | 324   | 341.3 |
|        |           | A/A      | 5 (1.7%)       | 4 (1.5%)       | 0.26 (0.02–3.61) |       |      |      |
|        | Overdominant | G/G-A/A  | 256 (87.1%)    | 231 (86.5%)    | 1.00           | 0.050 | 321.3 | 338.6 |
|        |           | A/G      | 38 (12.9%)     | 36 (13.5%)     | 0.40 (0.15–1.02) | 0.024* | 320   | 337.4 |
|        | Log-additive | —        | —              | —              | 0.41 (0.18–0.91) |       |      |      |

AIC: Akaike’s Information criterion;  
BIC: Bayesian Information criterion;  
*p value ≤ 0.05 indicates statistical significance.

populations [8]. Rs3783546 and rs2853550 were associated with erythematous [18] and rheumatoid arthritis [19], respectively. So that we speculated that rs3783550, rs3783546 and rs2853550 play an important role in chronic inflammatory disease, but three SNPs were not significantly associated with AS risk, only were associated with AS in different model in our study. That result might be due to differences among different regions of the world, which needs us to do further research to verify the results. Despite this study showed three SNPs (rs3783550, rs3783546 andrs2853550) associated with AS susceptibility in the different model, some limitations should be considered. First, as the incidence of ankylosing spondylitis is low, so that the sample size of our study was relatively small. There may be some false positive results, but it has been able to explain the trend of IL-1A and IL-1B in patients with ankylosing spondylitis. In the future we will recruit more samples included in our future studies to verify our results. Second, the heterogeneity in living conditions was not evaluated in this study, which has contributed to the progress in elucidating the pathogenesis of AS.

In conclusion, our study has described the association between rs3783550 (IL-1A), rs3783546 (IL-1A) and rs2853550 (IL-1B) and AS risk and between a new haplotype, “TCG”, of rs3783550, rs3783546 and...
rs2853550 and AS in Chinese Han population. Therefore, the results provide additional evidence for the relationships between genetic variants and AS susceptibility in the Hainan population. Moreover, a large number of genetic risk factors for AS should be investigated and validated to fully understand the pathogenesis of AS. Further studies will focus on the functional experiments based on the relevant genes on animal models, to investigate detailed mechanism involved.

**MATERIALS AND METHODS**

**Study participants**

We recruited a total of 267 patients diagnosed with AS and 297 controls from 2014 to 2016 among Han Chinese. All the subjects were treated by the Second Affiliated Hospital of Inner Mongolia Medical University. All participants signed informed written consent. All cases were verified, and patients were recruited without age, or disease stage restriction and who were previously healthy. AS was defined by the modified New York diagnostic criteria [20]. In all cases the diagnosis of AS was confirmed by a qualified rheumatologist and was followed by examination or telephone interview. In cases with an atypical history or no previous radiographic evidence, pelvic and lumbosacral spine radiographs were obtained and attending general practitioners were contacted to confirm diagnosis. All cases were HLA-B27 positive. To reduce the potential environmental and therapeutic factors impacting the variation of complex human diseases, we performed detailed recruitment and set exclusion criteria to exclude subjects with chronic disease and conditions involving vital organs (brain, liver, heart, and lung). Controls were selected unrelated and randomly. Among control individuals, none had any chronic diseases. The use of samples was approved by the Human Research Committee of the Second Affiliated Hospital of Inner Mongolia Medical University for Approval of Research Involving Human Subjects. The personal characteristics of the participants are listed in Table 1.

**SNP selection and genotyping**

Among the 12 SNPs we selected, rs16944 in IL-1B [5] was chosen from previously published polymorphisms associated with AS, others were randomly chosen from the published genes (IL-1A and IL-1B) associated with AS. Minor allele frequencies of all SNPs were > 5%, in the HapMap of the Chinese Han CHB population. We adopted Gold Mag-Mini Whole Blood Genomic DNA Purification Kit (GoldMagCo. Ltd. Xi’an City, China) to extract DNA that was from whole blood. Quantification of the extracted DNA was performed using NanoDrop2000. Genotyping was done with the Sequenom MassARRAY RS1000 system using the standard protocol recommended by the manufacturer. The multiplexed SNP Mass EXTENDED assay was designed using Sequenom Mass-ARRAY Assay Design 3.0 Software [21]. Data management and analysis was done using SequenomTyper 4.0 Software. We use the Sequenom MassARRAY RS1000 system to analysis genotype, which was conform to the standard protocol recommended by the manufacturer.

**Statistical analysis**

We used Microsoft Excel and SPSS 18.0 (SPSS, Chicago, IL, USA) to perform statistical analyses. In this study, all $p$ values were two-sided, and $p \leq 0.05$ was regarded as getting statistical significance. Control genotype frequencies for each SNP were tested for departure from Hardy-Weinberg equilibrium ($HWE$) using Fisher’s exact test. The $\chi^2$ test was used to compare the distribution of marker alleles and genotypes in cases and controls [22]. Unconditional logistic regression analysis adjustment with age was used to test odds ratios (ORs) and 95% confidence intervals (CIs) [23]. Associations between SNPs and risks of AS were tested in genetic models by analysis with SNP Stats software, obtained from http://bioinfo.iconcologia.net. Values of OR and 95% CI were calculated as above. Akaike’s InformationCriterion (AIC) and Bayesian InformationCriterion (BIC) were applied to choose the best-fit model for each SNP. Finally, we used

---

**Table 4: IL-1A and IL-1B haplotype frequencies and the association with the risk of ankylosing spondylitis in case and control patients (adjusted sex and age)**

| Gene | SNPs | Haplotype | Freq (case) | Freq (control) | OR (95% CI) | $p$-value* |
|------|------|-----------|-------------|----------------|-------------|------------|
| IL-1A | rs3783550/rs3783546/rs2856838 | GGG | 0.662 | 0.680 | 1 (referent) | — |
|      |      | TCA | 0.252 | 0.237 | 0.72 (0.44–1.18) | 0.19 |
|      |      | TCG | 0.086 | 0.083 | 0.36 (0.16–0.81) | 0.014* |
|      |      | CAGC | 0.530 | 0.517 | 1 (referent) | — |
| IL-1B | rs1143630/rs1143627/rs16944/ rs1143623 | GGAG | 0.223 | 0.255 | 1.08 (0.68–1.73) | 0.74 |
|      |      | TGAG | 0.178 | 0.151 | 0.89 (0.52–1.52) | 0.67 |
|      |      | GGAC | 0.066 | 0.070 | 0.68 (0.30–1.56) | 0.37 |

*p value ≤ 0.05 indicates statistical significance.
the SHEsis software (http://analysis.bio-x.cn/myAnalysis.php) to estimate the pairwise linkage disequilibrium (LD) and haplotype construction [24].

CONFLICTS OF INTEREST

All Authors declare that they have no conflicts of interest.

REFERENCES

1. Myrand S, Sekiguchi K, Man M, Lin X, Tzeng R, Teng C, Hee B, Garrett M, Kikkawa H, Lin C. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008; 84:347–361.

2. Tsui FW, Tsui HW, Akram A, Haroon N, Inman RD. The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. The application of clinical genetics. 2014; 7:105–115.

3. Brown MA, Edwards S, Hoyle E, Campbell S, Laval S, Daly AK, Pile KD, Calin A, Ebringer A, Weeks DE, Wordsworth BP. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol genet. 2000; 9:1563–1566.

4. Maksymowycz WP, Reeve JP, Reveille JD, Akey JM, Buenviaje H, O’Brien L, Peloso PM, Thomson GT, Jin L, Russell HS. High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Arthritis Rheumatol. 2003; 48:2011–2018.

5. Timms AE, Crane AM, Sims AM, Cordell HJ, Bradbury LA, Abbott A, Coyne MR, Beynon O, Herzberg I, Duff GW, Calin A, Cardon LR, Wordsworth BP, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet. 2000; 9:1563–1566.

6. McGarry F, Neilly J, Anderson N, Sturrock R, Field M. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology. 2001; 40:1359–1364.

7. van der Paardt M, Crusius JB, Garcia-Gonzalez MA, Baudoin P, Kostense PJ, Alizadeh BZ, Dijkmans BA, Pena AS, van der Horst-Bruinsma IE. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology. 2002; 41:1419–1423.

8. Maksymowycz WP, Rahman P, Reeve JP, Gladman DD, Peddle L, Inman RD. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheumatol. 2006; 54:974–985.

9. Sims AM, Timms AE, Bruges-Armas J, Burgos-Vargas R, Chou CT, Doan T, Dowling A, Fialho RN, Gergely P, Gladman DD, Inman R, Kauppi M, Kaarela K, et al. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann rheum dis. 2008; 67:1305–1309.

10. van der Pouw Kraan CT, Baggen JM, van Bodegraven AA, Mulder CJ, Zwiers A, Geerts D, Kraal G, Horrevoets AJ, Bouma G. Defective IL-1A expression in patients with Crohn’s disease is related to attenuated MAP3K4 signaling. Hum immunol. 2012; 73:912–919.

11. Nemetz A, Toth M, Garcia-Gonzalez MA, Zagony T, Feher J, Pena AS, Tulassay Z. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut. 2001; 49:644–649.

12. Johnson K, Hashimoto S, Lotz M, Pritzker K, Terekhtauba R. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol. 2001; 159:149–163.

13. Bioque G, Crusius JB, Koutrubakis I, Bouma G, Kostense PJ, Meuwissen SG, Pena AS. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol. 1995; 102:379–383.

14. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000; 404:398–402.

15. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics. 1994; 19:382–384.

16. Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis. 1999; 58:196–98.

17. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, Voronov E, Dinarello CA, Apte RN. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. P Natl Acad Sci USA. 2004; 101:2434–2439.

18. Solus JF, Chung CP, Oeser A, Li C, Rho YH, Bradley KM, Kawai VK, Smith JR, Stein CM. Genetics of serum concentration of IL-6 and TNFalpha in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis. Clin Rheumatol. 2015; 34:1375–1382.

19. Vaidya B, Pearce SH, Charlton S, Marshall N, Rowan AD, Griffiths ID, Kendall-Taylor P, Cawson TE, Young-Min S. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology. 2002; 41:180–183.

20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheumatol. 1984; 27:361–368.

21. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Current
protocols in human genetics / editorial board, Jonathan L Haines [et al]. 2009; Chapter 2:Unit 2 12.

22. Adamec C. [Example of the Use of the Nonparametric Test. Test X2 for Comparison of 2 Independent Examples]. Ceskoslovenske zdravotnictvi. 1964; 12:613–619.

23. Bland JM, Altman DG. Statistics notes. The odds ratio. Bmj. 2000; 320:1468.

24. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005; 15:97–98.